Abstract
Q uinolones provide a cost-effective treatment option for infection because the availability of potent oral formulations facilitates early conversion to oral therapy, with resultant cost savings compared with standard courses of IV therapy. This was the conclusion of Dr Peggy McKinnon who holds the position of clinical specialist, Infectious Diseases Pharmacotherapy at Detroit Receiving Hospital, Michigan, US. The new extended-spectrum quinolones are likely to increase the potential cost savings that can be achieved by early IV-to-oral switch therapy. The potential pharmacoeconomic role for the quinolones was discussed at the 32nd Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) [ Atlanta, Georgia, US; December 1997 ].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
